Joyzyme Group Limited (HKG:8622)

Market Cap	177.84M +12.8%
Revenue (ttm)	31.47M +11.5%
Net Income	-5.57M
EPS	-0.01
Shares Out	515.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,960,000
Average Volume	436,400
Open	0.3250
Previous Close	0.3250
Day's Range	0.3000 - 0.3500
52-Week Range	0.2850 - 0.7500
Beta	0.64
RSI	55.75
Earnings Date	Mar 27, 2026

About Joyzyme Group

Joyzyme Group Limited, an investment holding company, engages in the research, production, and sale of male fertility in-vitro diagnostic (IVD) reagents in the People's Republic of China. The company provides biological reagents, including male fertility IVD reagents, parasite antibody detection reagents, and Epstein-Barr virus antibody detection reagent; and auxiliary reproductive supplies and equipment. The company sells its products directly to hospitals and medical institutions, as well as to distributors. The company was formerly known as ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 98
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 8622

Financial Performance

In 2025, Joyzyme Group's revenue was 28.28 million, an increase of 11.53% compared to the previous year's 25.36 million. Losses were -5.01 million, 20.4% more than in 2024.

Financial numbers in CNY